Arreguín V, Cebada M, Simón JI, Sifuentes-Osornio J, Bobadilla-del Valle M, Macías AE

Language: Spanish
References: 38
Page: 239-245
PDF size: 68.25 Kb.

ABSTRACT

Objective. To determine the antibiotic resistance of urinary pathogens in ambulatory patients from Mexico City, in order to infer therapeutic options in environments of high resistance. Methods. Cross sectional survey performed between July 2006, and January 2007, in patients ≥ 3 year-old from a private institution. Cultured organisms were identified with a commercial biochemical system. For common antibiotics, susceptibility was performed by broth microdilution with a commercial system; for fosfomycin tromethamine, the disk diffusion test was performed. Results. From 1685 urine specimens, 257 (15.3%) yielded a positive culture; 215 (83.7%) from women and 42 (16.3%) from men. Global resistance was the following: ampicillin, 68.4%; co-amoxiclav, 19.5%; ciprofloxacin, 36.3%; cephalothin, 64.7%; ceftriaxone, 12.2%; cefuroxime, 18.7%; nitrofurantoin, 19%; trimethoprim-sulphamethoxazol, 53.4%; gentamicin, 18.9%; and fosfomycin tromethamine, 0.8%. Escherichia coli was the main pathogen, with 203 (79%) isolations; its specific resistance was similar to the global one, and its production of extended-spectrum beta-lactamases (ESBLs) was 9.4%. Conclusions. The high resistance rate found is alarming; we have few options for the initial treatment of urinary tract infections in ambulatory patients. To control the problem, health authorities must regulate the indiscriminate use of antibiotics.

REFERENCES

1. Ochoa SC, Eiros BJM, Pérez MC, Inglada GL y grupo de estudio de los tratamientos antibióticos. Etiología de las infecciones del tracto urinario y sensibilidad de los uropatógenos a los antimicrobianos. Rev Esp Quimioterap 2005; 18: 124-35.

2. Le TP, Miller LG. Empirical therapy for uncomplicated urinary tract infections in an era of increasing antimicrobial resistance: a decision and cost analisis. Clin Infect Dis 2001; 33: 615-21.

3. Andrade SS, Sader HS, Jones RN, Pereira AS, Pignatari ACC, Gales AC. Increased resistance to first-line agents among bacterial pathogens isolated from urinary tract infections in Latin America: time for local guidelines? Mem Inst Oswaldo Cruz 2006; 101: 741-8.

4. Sifuentes-Osornio J, Donis-Hernandez J, Arredondo-Garcia JL, Escalante-Ramirez O, Macias A, Muñoz JM, et al. Report on bacterial resistance: pilot study of six mexican centers. In: Salvatierra- Gonzalez R, Benguigui Y. Antimicrobial resistance in the Americas: Magnitude and containment of the problem. Washington, D.C.: Pan American Health Organization; 2000, p. 158-62.

5. Gupta K, Sahm DF, Mayfield D, Stamm WE. Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in women: a nationwide analysis. Clin Infect Dis 2001; 33: 89-94.

6. Gupta K, Hooton TM, Stamm WE. Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections. Ann Intern Med 2001; 135: 41-50.

7. Kahlmeter G, Menday P. Cross-resistance and associated resistance in 2478 Escherichia coli isolates the pan-european ECOSENS project surveying the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections. J Antimicrob Chemother 2003; 52: 128-31.

8. Dromigny JA, Nabeth P, Juergens-Behr A, Perrier-Gros- Claude JD. Risk factors for antibiotic-resistant Escherichia coli isolated from community-acquired urinary tract infections in Dakar, Senegal. J Antimicrob Chemother 2005; 56: 236-9.

9. Murray BE, Mathewson JJ, DuPont HL, Ericsson CD, Reves RR. Emergence of resistant fecal Escherichia coli in travelers not taking prophylactic antimicrobial agents. Antimicrob Agents Chemother 1990; 34: 515-8.

10. Isenberg HD, Clarke LM, Della-Latta P, Denys GA, Garcia LS, Hazen KC, et al. Essential procedures for clinical microbiology. Washington, DC: ASM Press; 1998.

11. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: Fifteenth International Supplement. M2-A8. 2005; 25: 11-58.

12. Barry AL, Fuchs PC. In vitro susceptibility testing procedure for fosfomycin tromethamine. Antimicrob Agents Chemother 1991; 35: 1235-8.

13. Fuchs PC, Barry AL, Brown SD. Susceptibility testing quality control studies with fosfomycin tromethamine. Eur J Clin Microbiol Infect Dis 1997; 16: 538-40.

14. Goldstein FW, and the multicentre study group. Antibiotic susceptibility of bacterial strains isolated from patients with community- acquired urinary tract infections in France. Eur J Clin Microbiol Infect Dis 2000; 19: 112-7.

15. Goettsch W, Pelt WV, Nagelkerke N, Hendrix MGR, Buiting AGM, Petit PL, et al. Increasing resistance to fluoroquinolones in Escherichia coli from urinary tract infections in The Netherlands. J Antimicrob Chemoter 2000; 46: 223-8.

16. Olafsson M, Kristinsson KG, Sigurdsson JA. Urinary tract infections, antibiotic resistance and sales of antimicrobial drugs. An observational study of uncomplicated urinary tract infections in Icelandic women. Scand J Prim Health Care 2000; 18: 35-8.

17. Kerrn MB, Klemmensen T, Frimodt-M?ller, Espersen F. Susceptibility of Danish Escherichia coli strains isolated from urinary tract infections and bacteraemia, and distribution of sul genes conferring sulphonamide resistance. J Antimicrob Chemoter 2002; 50: 513-6.

18. Kahlmeter G, Menday P, Cars O. Non-hospital antimicrobial usage and resistance in community-acquired Escherichia coli urinary tract infection. J Antimicrob Chemother 2003; 52: 1005-10.

19. Farrell DJ, Morrissey I, De Rubeis D, Robbins M, Felmingham D. A UK multicentre study of the antimicrobial susceptibility of bacterial pathogens causing urinary tract infection. J Infect 2003; 46: 94-100.

20. Jureen R, Digranes A, Baerheim A. [Urinary tract pathogens in uncomplicated lower urinary tract infections in women in Norway]. Tidsskr Nor Laegeforen 2003; 123: 2021-2. [Article in Norwegian].

21. Lorente GJA, Placer SJ, Salvadó CM, Segura AC, Gelabert-Mas A. Evolución de la resistencia antibiótica en las infecciones urinarias adquiridas en la comunidad. Rev Clin Esp 2005; 205: 259-64.

22. Salas CM, Gil-Setas A, Mazón A. Etiología y sensibilidad antibiótica de las infecciones extrahospitalarias más frecuentes. An Sist Sanit Navar 2006; 29: 27-36.

23. Kurutepe S, Surucuoglu S, Sezgin C, Gazi H, Gulay M, Ozbakkaloglu B. Increasing antimicrobial resistance in Escherichia coli isolates from community-acquired urinary tract infections during 1998-2003 in Manisa, Turkey. Jpn J Infect Dis 2005; 58: 159-61.

24. Zhanel GG, Karlowsky JA, Harding GKM, Carrie A, Mazzulli T, et al. A Canadian national surveillance study of urinary tract isolates from outpatients: comparison of the activities of trimethoprim sulfametoxazole, ampicillin, mecillinam, nitrofurantoin, and ciprofoloxacin. Antimicrob Agents Chemother 2000; 44: 1089-92.

25. Karlowsky JA, Kelly LJ, Thornsberry C, Jones ME, Sahm DF. Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States. Antimicrob Agents Chemother 2002; 46: 2540-5.

26. Hryniewicz K, Szczypa K, Sulikowska A, Jankowski K, Betlejewska K, Hryniewicz W. Antibiotic susceptibility of bacterial strains isolated from urinary tract infections in Poland. J Antimicrob Chemother 2001; 47: 773-80.

27. Stratchounski LS, Rafalski VV. Antimicrobial susceptibility of pathogens isolated from adult patients with uncomplicated community-acquired urinary tract infections in the Russian Federation: two multicentre studies, UTIAP-1 and UTIAP-2. Int J Antimicrob Agents 2006; 28(Supp. 1): S4-S9.

28. Al-Ali SM, Al-Hamdan AS, Al-Jarki FA, Al-Faraj JMK, Al- Musalem SS. Antimicrobial resistance pattern in urinary tract pathogens and its impact on empirical therapy in general practice. Kuwait Medical Journal 2005; 37: 22-7.

29. Pedreira W, Anzalone L, Álvez M, Cafferatta A. Fosfomicina trometamol. Una opción terapéutica válida en infecciones urinarias bajas. Rev Med Uruguay 2003; 19: 107-16.

30. Biswas D, Gupta P, Prasad R, Singh V, Arya M, Kumar A. Choice of antibiotic for empirical therapy of acute cystitis in a setting of high antimicrobial resistance. Indian J Med Sci 2006; 60: 53-8.

31. Gobernado M. Fosfomicina. Rev Esp Quimioter 2003; 16: 15-40.

32. Patel SS, Balfour JA, Bryson HM. Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. Drugs1997; 53: 637-56.

33. Sánchez-Merino JM, Guillán MC, Fuster FC, López MR, Jiménez RM, García AJ. Sensibilidad microbiana de Escherichia coli en bacteriurias en el área sanitaria del bienio en el año 2003. Actas Urol Esp 2004; 28: 588-93.

34. Bretones Alcaraz JJ, Pino y Pino MD, Morales Torres M, Vivas- Pérez JJA, Molina Aparicio MJ, Garófano DV. Estudio observacional de los urocultivos y antibiogramas realizados ambulatoriamente en un área de salud. Medifam 2002; 12: 436-41.

35. Andreu A, Alós JI, Gobernado M, Marco F, de la Rosa M, García- Rodríguez JA, et al. Etiología y sensibilidad a los antimicrobianos de los uropatógenos causantes de la infección urinaria baja adquirida en la comunidad. Estudio nacional multicéntrico. Enferm Infecc Microbiol Clin 2005; 23: 4-9.

36. Ishihara S, Yokoi S, Masue N, Yamada T, Minamidate Y, Yasuda M, et al. Urinary tract-derived Escherichia coli resistant to co-trimoxazole in Japan, where the drug is seldom used for treating acute urinary tract infections. J Antimicrob Chemother 2002; 49: 881-2.

37. Pitout JDD, Nordman P, Laupland KB, Poirel L. Emergence of Enterobacteriaceae producing extended-spectrum ß-lactamases (ESBLs) in the community. J Antimicrob Chemother 2005; 56: 52-9.

38. Tzouvelekis LS, Vatopoulos AC, Katsanis G, Tzelepi E. Rare case of failure by an automated system to detect extendedspectrum ß-lactamase in a cephalosporin-Resistant Klebsiella pnemoniae isolate. J Clin Microbiol 1999; 37: 2388.